Polyvinyl Butyrate Nanoparticles as Butyrate Donors for Colitis Treatment.
Animals
Biocompatible Materials
/ chemical synthesis
Butyric Acid
/ chemistry
Cells, Cultured
Colitis
/ chemically induced
Dextran Sulfate
Disease Models, Animal
Drug Carriers
/ chemistry
Male
Materials Testing
Mice
Mice, Inbred C57BL
Molecular Structure
Nanoparticles
/ chemistry
Particle Size
Polyvinyls
/ chemical synthesis
RAW 264.7 Cells
butyrate
inflammatory bowel disease
nanoparticles
polyvinyl butyrate
vitamin D3
Journal
ACS applied bio materials
ISSN: 2576-6422
Titre abrégé: ACS Appl Bio Mater
Pays: United States
ID NLM: 101729147
Informations de publication
Date de publication:
15 03 2021
15 03 2021
Historique:
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
29
3
2022
Statut:
ppublish
Résumé
Butyrate has been attracting attention for the suppression of inflammatory bowel disease (IBD). However, clinical trials of butyrate for IBD treatment have resulted in controversial outcomes, likely owing to the adverse effect of butyrate on the intestinal epithelium that was observed at high butyrate concentrations. Herein, we propose polyvinyl butyrate (PVBu) nanoparticles (NPs) as butyrate donors for delivery to the lower part of the intestine for the treatment of colitis. The PVBu NPs suppressed the inflammatory activation of macrophages
Identifiants
pubmed: 35014354
doi: 10.1021/acsabm.0c01105
doi:
Substances chimiques
Biocompatible Materials
0
Drug Carriers
0
Polyvinyls
0
Butyric Acid
107-92-6
polyvinylbutyral
9003-62-7
Dextran Sulfate
9042-14-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM